Adjuvant use of rifampin for refractory intrahepatic cholestasis of pregnancy

James Liu, Amanda M. Murray, Erin B. Mankus, Kayla E. Ireland, Ometeotl M. Acosta, Patrick S. Ramsey

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


BACKGROUND: Intrahepatic cholestasis of pregnancy is an incompletely understood disease that poses significant fetal risks, including stillbirth. Treatment of intrahepatic cholestasis of pregnancy is aimed at relieving maternal symptoms and improving fetal outcomes. CASE: A 21-year-old gravid woman, 3 para 0111, presented at 27 2/7 weeks of gestation with severe intrahepatic cholestasis of pregnancy. Her clinical course was refractory to first-line therapy with ursodiol, and she was started on rifampin with rapid improvement of symptoms and transaminitis. Despite maternal improvement, she was delivered at 31 weeks of gestation for persistent nonreassuring fetal status. CONCLUSION: Rifampin may be an effective adjunctive therapy for intrahepatic cholestasis of pregnancy refractory to ursodiol alone. Additional research is needed to assess short-term and long-term maternal and newborn outcomes, because fetal deterioration still occurred in spite of maternal improvement.

Original languageEnglish (US)
Pages (from-to)678-681
Number of pages4
JournalObstetrics and gynecology
Issue number3
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Adjuvant use of rifampin for refractory intrahepatic cholestasis of pregnancy'. Together they form a unique fingerprint.

Cite this